Bi- and multispecific antibodies and combination therapy remain one of the most important and central areas of antibody engineering. Innovative platforms and engineering approaches have created the next generation of multispecific antibodies with novel functionalities and features. This conference will highlight efforts to identify attributes early in the process to make necessary improvements to constructs and avoid failures in the clinic late in the development process. Join the leading faculty in this field as we explore one of the most exciting areas in biologics and discover what the newest platforms and engineering approaches are that promise an increasingly diverse array of new constructs and strategies that can achieve unprecedented efficacy.
Scientific Advisory Board:
Christian Klein, PhD, Head, Oncology Programs and Department Head, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharma Research & Early Development, pRED
Harald Kolmar, PhD, Professor and Head, Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt
Stefan Zielonka, PhD, Senior Director, Global Head of Antibody Discovery & Protein Engineering (ADPE) Research & Development, Merck Healthcare KGaA; Professor, Biomolecular Immunotherapy, Technische Universität Darmstadt